Janux Therapeutics (JANX) Interest Expenses (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Interest Expenses of $28.5 million for Q1 2026, down 78.27% year-over-year from $131.2 million in Q1 2025, and down 73.33% quarter-over-quarter from $106.8 million in Q3 2025.
Janux Therapeutics (JANX) Interest Expenses (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Interest Expenses for 7 consecutive years, with $28.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses fell 78.27% year-over-year to $28.5 million; the TTM figure through Mar 2026 stood at $28.5 million (down 78.27% YoY), while the FY2025 annual figure was $29.6 million, down 91.82% from the prior year.
- Interest Expenses fell to $28.5 million in Q1 2026 per JANX's latest filing, from $106.8 million in the prior quarter.
- Across five years, Interest Expenses topped out at $313.5 million in Q3 2024 and bottomed at $344000.0 in Q4 2022.
- Historically, Interest Expenses has averaged $101.4 million across 5 years, with a median of $37.8 million in 2022.
- Annual changes were most pronounced in 2024 — Interest Expenses surged 1979.37% — and 2026, when it tumbled 78.27%.
- Janux Therapeutics' Interest Expenses stood at $344000.0 in 2022, then soared by 4282.56% to $15.1 million in 2023, then soared by 1979.37% to $313.5 million in 2024, then slumped by 65.92% to $106.8 million in 2025, then slumped by 73.33% to $28.5 million in 2026.
- Business Quant data shows JANX's Interest Expenses at $28.5 million in Q1 2026, $106.8 million in Q3 2025, and $98.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | 38.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.57 Mn |
| Jun 30, 2026 | 38.57 Mn |
| Mar 31, 2026 | 28.50 Mn |
| Mar 31, 2026 | 28.50 Mn |
| Sep 30, 2025 | 106.84 Mn |
| Sep 30, 2025 | 106.84 Mn |
| Jun 30, 2025 | 98.68 Mn |
| Jun 30, 2025 | 98.68 Mn |
| Mar 31, 2025 | 131.17 Mn |
| Mar 31, 2025 | 131.17 Mn |
| Sep 30, 2024 | 313.49 Mn |
| Sep 30, 2024 | 313.49 Mn |
| Jun 30, 2024 | 286.88 Mn |
| Jun 30, 2024 | 286.88 Mn |
| Mar 31, 2024 | 253.76 Mn |
| Mar 31, 2024 | 253.76 Mn |
| Sep 30, 2023 | 15.08 Mn |
| Sep 30, 2023 | 15.08 Mn |
| Jun 30, 2023 | 36.61 Mn |
| Jun 30, 2023 | 36.61 Mn |